Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

COVID-19 Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-Controlled, Escalating Single Dose, Phase 1 & Phase 2 Study to Evaluate the Safety and Efficacy of Inhaled IBIO123 in Participants With Severe COVID-19 Illness

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05303376
• Other study ID #: IBIO-INH-002
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: February 22, 2022
• Est. completion date: June 27, 2023

Study information

• Verified date: September 2023
• Source: Immune Biosolutions Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 and phase 2, adaptive, placebo-controlled, double-blind, randomized single-dose study in participants with Severe COVID-19 illness.

Description:

In Phase 1, in hospital in a continuous observation setting the first cohort will recruit a total of 8 participants who will receive a single inhaled administration of the study treatment. This cohort will consist of 6 participants on active treatment at a dose of 5mg (0.5cc) of IBIO123 and 2 participants on placebo (0.5cc). Participants will be followed for a total duration of 7 days which is greater than 5 expected half-lives of the study drug in lungs. Therefore, after 7 days, negligible amount of the study drug should remain in the lungs of participants. Safety data will be collected and reviewed by a Data Monitoring Committee (DMC). If no stopping rules have been met, the DMC will recommend the dosing of the second cohort at the expected therapeutic dose of 10mg. If stopping rules have been met the DMC will recommend the termination of the study.

The second cohort will be recruited in hospital in continuous observation setting and recruit a total of 8 participants who will receive a single inhaled administration of the study treatment. This cohort will consist of 6 participants on active treatment at a dose of 10mg of IBIO123 (1 cc) and 2 participants on placebo (1 cc).

Participants will be followed for a total duration of 7 days which is greater than 5 expected half-lives of the study drug in lungs. Therefore, after 7 days, negligible amount of the study drug should remain in the lungs of participants. Safety data will be collected and reviewed by a Data Monitoring Committee (DMC). If no stopping rules have been met the DMC will recommend the phase 2 dose of 10mg. If stopping rules have been met the DMC will recommend a phase 2 dose of 5 mg.

In Phase 2, in the lead-in portion of the phase 2, the DMC will meet 7 days after the first 9 subjects (3 Placebo and 6 Active) have completed their day 7 visit to review safety information of these subjects that have been dosed with 10mg of IBIO123 on Days 1 and 3. If this dose regimen is deemed safe by the DMC, the phase 2 study enrolment will pursue and be completed at 10mg on Day 1 and 10 mg on Day 3. If stopping rules were obtained during the Safety review, the study enrolment will be pursued with a single dose of 10mg of IBIO 123 on Day 1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 123
• Est. completion date: June 27, 2023
• Est. primary completion date: June 27, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Age

1. Are =18 years of age at the time of randomization

Disease Characteristics

2. Are currently hospitalized since less or equal than 3 days for COVID-19 respiratory illness

3. Must have a positive SARS-CoV-2 viral infection determination prior to randomisation. For the phase 2 portion of the study only, the test must be performed within 24 hours before randomisation. Test can be a PCR or an antigen test originated from the institution or any government approved testing site. If the original test result is greater than 24 hours from randomisation, a rapid antigen must be performed at bedside by the study team to determine eligibility

Sex

4. Are men or non-pregnant women Reproductive and Contraceptive agreements and guidance is provided in Appendix 2. Contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies.

Study Procedures

5. Understand and agree to comply with planned study procedures

6. Agree to the collection of nasopharyngeal swabs and venous blood

Informed Consent

7. The participant or legally authorized representative give signed informed consent

Exclusion Criteria:

Medical Conditions

8. COVID-19 onset of symptoms began more than 10 days before randomisation

9. Currently intubated or intubation is planned within the next 24 hours

10. Have known allergies to any of the components used in the formulation of the interventions

11. Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention

12. Have any co-morbidity requiring surgery within <7 days, or that is considered life- threatening within 29 days

13. Have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study.

Other Exclusions

14. Have received treatment with a SARS-CoV-2 specific monoclonal antibody

15. Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.

16. Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study

17. Are pregnant or breast feeding

18. Are investigator site personnel directly affiliated with this study

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• IBIO123
5 or 10 mg

Other:
• Placebo
matching placebo

Locations

Country	Name	City	State
South Africa	JOHESE UNITAS Hospital	Lyttelton	Centurion
South Africa	JOHESE ZAH Hospital	Pretoria	Gauteng
Ukraine	Central City Clinical Hospital of Ivano-Frankivsk City Council	Ivano-Frankivs'k	Ivano-Frankivsk Oblast
Ukraine	City Clinical Hospital #1 of Ivano-Frankivsk City Council	Ivano-Frankivs'k	Ivano-Frankivsk Oblast
Ukraine	Hospital ?1" of the Zhytomyr City Council	Zhytomyr	Zhytomyrs'ka Oblast

Sponsors (1)

Lead Sponsor	Collaborator
Immune Biosolutions Inc

Countries where clinical trial is conducted

South Africa,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1: Characterize the effect of IBIO123 compared to placebo on safety and tolerability	• Safety assessments such as AEs and SAEs	Baseline to Day 7
Primary	Phase 2: Characterize the effect of IBIO123 compared to placebo on SARS-CoV-2 viral load and viral clearance	• Change from baseline to Day 5 (± 2 days) in SARS-CoV-2 viral load	Baseline to Day 5
Secondary	Phase 1: Characterize the effect of IBIO123 compared to placebo on SARS-CoV-2 viral load and viral clearance	• Change from baseline to Day 7 (± 2 days) in SARS-CoV-2 viral load	Baseline to Day 7
Secondary	Phase 2: Characterize the effect of IBIO123 compared to placebo on COVID-19 clinical progression	• Change over time from baseline to Day 29 (± 2 days) in COVID-19 WHO Clinical Progression Scale	Baseline to Day 29
Secondary	Phase 2: Characterize the effect of IBIO123 compared to placebo on overall participant clinical status	• Proportion (percentage) of participants who experience these events by Day 29; ICU admission; intubation; Mortality; Discharge from Hospitalisation	Baseline to Day 29
Secondary	Phase 2: Characterize the effect of IBIO123 compared to placebo on safety and tolerability	• Safety assessments such as AEs and SAEs	Baseline to Day 29
Secondary	Phase 2: Characterize the effect of IBIO123 compared to placebo on length of stay in hospital	• Mean duration of hospitalisation and ICU care (days)	Baseline to Day 29
Secondary	Phase 2: Characterize the effect of IBIO123 compared to placebo on oxygen supplementation and ventilation needs	Mean duration of oxygen treatment (days) and Incidence of Intubation and Mean duration of Intubation (days)	Baseline to Day 29
Secondary	Phase 2: Characterize the pharmacokinetics of IBIO123	IBIO123 mean plasma concentration	Days 1, 3, 7 and 29
Secondary	Phase 2: Characterize the immunogenicity of IBIO123	Assessment of Anti-drug antibodies of IBIO123 at Day 1 and 29	Baseline to Day 29